Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Oncologist

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/THEONCOLOGIST.6-2-133PMID 11306725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Winter Scene

  2014cited by this paper
• A Review of the Antitumour Activity of Vinorelbine in Breast Cancer

  2012cited by this paper
• Current status of Taxotere® (docetaxel) as a new treatment in breast cancer

  2004cited by this paper
• Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study

  2004cited by this paper
• DRUG DEVELOPMENT TEAMS*

  2001cited by this paper
• Cancer Statistics, 2001

  2001cited by this paper
• First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody)

  2000cited by this paper
• Herceptin and vinorelbine for HER2-positive metastatic breast cancer : a phase II study

  2000cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer.

  2000cited by this paper
• Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

  2000cited by this paper
• High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer.

  2000cited by this paper
• A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma

  2000cited by this paper
• Docetaxel administered on a weekly basis for metastatic breast cancer.

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.

  2000cited by this paper
• Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

  2000cited by this paper
• Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.

  2000cited by this paper
• Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.

  2000cited by this paper
• Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.

  1999cited by this paper
• The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

  1999cited by this paper
• Single-agent paclitaxel in the treatment of breast cancer: phase I and II development.

  1999cited by this paper
• Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

  1999cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

  1999cited by this paper
• Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

  1999cited by this paper
• Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

  1999cited by this paper
• Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.

  1999cited by this paper
• Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.

  1999cited by this paper
• Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

  1999cited by this paper
• Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.

  1999cited by this paper
• Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

  1999cited by this paper
• Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.

  1999cited by this paper
• Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.

  1999cited by this paper
• Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Adjuvant systemic therapy for primary breast cancer.

  1999cited by this paper
• Monoclonal Antibody-Based Therapy of Cancer

  1998cited by this paper
• Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

  1998cited by this paper
• Treatment of breast cancer.

  1998cited by this paper
• A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.

  1998cited by this paper
• Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.

  1997cited by this paper
• A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee.

  1997cited by this paper
• Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.

  1997cited by this paper
• A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer

  1997cited by this paper
• Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

  1997cited by this paper
• Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.

  1997cited by this paper
• Bcl2 is the guardian of microtubule integrity.

  1997cited by this paper
• Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.

  1997cited by this paper
• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  1996cited by this paper
• Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.

  1996cited by this paper
• Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

  1996cited by this paper
• Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

  1996cited by this paper
• A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.

  1996cited by this paper
• Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

  1996cited by this paper
• Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.

  1996cited by this paper
• Vinorelbine: an overview.

  1996cited by this paper
• Advanced breast cancer: a phase II trial with gemcitabine.

  1995cited by this paper
• Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.

  1995cited by this paper
• Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

  1995cited by this paper
• Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

  1995cited by this paper
• Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

  1995cited by this paper
• Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.

  1995cited by this paper
• Inactivation of Bcl-2 by phosphorylation.

  1995cited by this paper
• Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

  1995cited by this paper
• Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

  1995cited by this paper
• Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

  1994cited by this paper
• Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.

  1994cited by this paper
• Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.

  1994cited by this paper
• Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.

  1994cited by this paper
• Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.

  1994cited by this paper
• Stability of HER-2/neu expression over time and at multiple metastatic sites.

  1993cited by this paper
• Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

  1993cited by this paper
• Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

  1993cited by this paper
• The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

  1993cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.

  1991cited by this paper
• Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group.

  1989cited by this paper
• Phase-II study of Navelbine in advanced breast cancer.

  1989cited by this paper
• A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.

  1988cited by this paper
• Chemotherapy Versus Chemoimmunotherapy (CAF v CAFVP v CMF Each t MER) for Metastatic Carcinoma of the Breast: A CALGB Study

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.

  1987cited by this paper
• [Treatment of metastatic breast cancer].

  1986cited by this paper
• A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5‐drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study

  1984cited by this paper
• The importance of dose intensity in chemotherapy of metastatic breast cancer.

  1984cited by this paper
• Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project.

  1983cited by this paper
• Promotion of microtubule assembly in vitro by taxol

  1979cited by this paper
• Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG

  1979cited by this paper
• A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

  1978cited by this paper
• Adriamycin versus methotrexate in five‐drug combination chemotherapy for advanced breast cancer. A randomized trial

  1978cited by this paper
• A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

  1977cited by this paper
• Diseases of the Breast

  1971cited by this paper
• Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

  1971cited by this paper
• [Treatment of breast cancer].

  1971cited by this paper
• Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma.

  1966cited by this paper
• Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma.

  1966cited by this paper

• Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy

  2025cites this paper
• Taohong Siwu decoction enhances the chemotherapeutic efficacy of doxorubicin by promoting tumor vascular normalization.

  2024cites this paper
• Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids

  2023cites this paper
• Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences

  2022cites this paper
• Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer

  2022cites this paper
• Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data

  2022cites this paper
• Lumbar spine metastasis in a breast cancer survivor after twelve years of disease-free survival

  2020cites this paper
• Primary Tumor Removal Improves the prognosis In Patients with Stage IV Breast Cancer: A Population-Based Study (Cohort Study).

  2020cites this paper
• Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies.

  2019cites this paper
• Drug Combinations in Breast Cancer Therapy

  2019cites this paper
• Effects of increased accumulation of doxorubicin due to emodin on efflux transporter and LRP1 expression in lung adenocarcinoma and colorectal carcinoma cells

  2018cites this paper
• Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8

  2018cites this paper
• Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation

  2018cites this paper
• Dual-functional cyclic peptide switch on mesoporous nanocontainers for selective CD44 targeting and on–off gatekeeping triggered by conformational transformation

  2018cites this paper
• Earth-abundant and environment friendly organic–inorganic hybrid tetrachloroferrate salt CH3NH3FeCl4: structure, adsorption properties and photoelectric behavior

  2018cites this paper
• Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.

  2017cites this paper
• Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer

  2017cites this paper
• Metastatic human breast cancer to the spine produces mechanical hyperalgesia and gait deficits in rodents.

  2017cites this paper
• Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents

  2016cites this paper
• Olive leaf extract containing oleuropein modulates the cytotoxic effect of epirubicin on breast cancer cells depending on the cell line

  2016cites this paper
• What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future

  2016cites this paper
• Chromatin immunoprecipitation-sequencing predicts p300 binding sites in the MCF7 human breast cancer cell line

  2015cites this paper
• siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.

  2015cites this paper
• A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer

  2015cites this paper
• Selenate specifically sensitizes drug-resistant cancer cells by increasing apoptosis via G2 phase cell cycle arrest without P-GP inhibition.

  2015cites this paper
• Chromatin immunoprecipitation-sequencing predicts p300 binding sites in the MCF7 human breast cancer cell line.

  2015cites this paper
• Curcumin Reduces Cytotoxicity of 5-Fluorouracil Treatment in Human Breast Cancer Cells

  2015cites this paper
• Methotrexate- and cyclophosphamide-embedded pure and strontiumsubstituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells.

  2014cites this paper
• Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.

  2014cites this paper
• Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer

  2014cites this paper
• Diagnosis and surgical management of breast cancer metastatic to the spine.

  2014cites this paper
• Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7

  2014cites this paper
• Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?

  2014cites this paper
• Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy.

  2014cites this paper
• Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma

  2013cites this paper
• Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles.

  2013cites this paper
• Nanocarriers for tracking and treating diseases.

  2013cites this paper
• A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.

  2013cites this paper
• Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

  2013cites this paper
• Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens

  2013cites this paper
• Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer

  2013cites this paper
• Importance of the development time of isolated bone metastasis in breast cancer

  2012cites this paper
• Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs

  2012cites this paper
• A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

  2012influential citation
• Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.

  2012cites this paper
• Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

  2012cites this paper
• PHARMACOKINETIC AND PHARMACOLOGIC STUDY OF TWO P-GLYCOPROTEIN MODULATING AGENTS COMBINED WITH DOXORUBICIN

  2012cites this paper
• Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.

  2012cites this paper
• A Phase II Study of Combination Chemotherapy with Capecitabine and Intravenous Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes: Efficacy and Tolerance

  2011cites this paper
• Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

  2011cites this paper
• Surgery Followed by Radiotherapy for the Treatment of Metastatic Epidural Spinal Cord Compression From Breast Cancer

  2011cites this paper
• Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

  2011cites this paper
• Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers

  2011cites this paper
• Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study

  2011cites this paper
• Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.

  2010cites this paper
• Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate

  2010cites this paper
• Investigating age varying effect of access to cancer care on immediate choice of chemotherapy among elderly women with metastatic breast cancer

  2010cites this paper
• Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines.

  2010cites this paper
• Matrix Metalloproteinase-1 Expression Can Be Upregulated through Mitogen-Activated Protein Kinase Pathway under the Influence of Human Epidermal Growth Factor Receptor 2 Synergized with Estrogen Receptor

  2010cites this paper
• Present and future evolution of advanced breast cancer therapy

  2010cites this paper
• Implications of Anthracycline‐Resistant and Taxane‐Resistant Metastatic Breast Cancer and New Therapeutic Options

  2010cites this paper
• SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin.

  2009cites this paper
• The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.

  2009cites this paper
• Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)

  2009cites this paper
• The role of surgery in breast cancer patients with isolated bone metastases at the time of diagnosis

  2009cites this paper
• Systemic Therapy of Metastatic Breast Cancer: The Truth Beyond the Clinical Trials

  2009cites this paper
• Development of novel RNA- and protein-based cancer therapeutics by either silencing of potential oncogenes or active restoration of a tumor suppressor gene

  2009cites this paper
• Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.

  2009cites this paper
• Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model

  2009cites this paper
• The changing face of HDAC inhibitor depsipeptide.

  2009cites this paper
• Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer

  2009cites this paper
• Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.

  2008cites this paper
• Blood Flow and Glucose Metabolism in Stage IV Breast Cancer: Heterogeneity of Response During Chemotherapy

  2008influential citation
• Clinical studies with epothilones for the treatment of metastatic breast cancer.

  2008cites this paper
• Preclinical investigations with epothilones in breast cancer models.

  2008cites this paper
• Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.

  2008cites this paper
• Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer

  2008cites this paper
• A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

  2008cites this paper
• Richtlijn behandeling van het mammacarcinoom

  2008cites this paper
• Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

  2008cites this paper
• Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

  2008cites this paper
• A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

  2007cites this paper
• Significance of interleukin-6 (IL-6) in breast cancer (review)

  2007cites this paper
• A Phase II Trial of Vinorelbine and Pegylated Liposomal Doxorubicin in Patients With Pretreated Metastatic Breast Cancer

  2007cites this paper
• Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis

  2007influential citation
• Improvement of Safety Profile of Docetaxel by Weekly Administration in Patients with Metastatic Breast Cancer

  2007cites this paper
• Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patients

  2007influential citation
• Targeting the microtubules in breast cancer beyond taxanes: the epothilones.

  2007cites this paper
• Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease

  2007influential citation
• Comparative analysis of xanafide cytotoxicity in breast cancer cell lines

  2007cites this paper
• CARACTERIZACIÓN DEL EFECTO ANTICANCEROSO E IDENTIFICACIÓN DE DIANAS MOLECULARES DE PRINCIPIOS ACTIVOS PROCEDENTES DE Serratia marcescens

  2007cites this paper
• Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.

  2007cites this paper
• Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988–2003 SEER Data

  2007cites this paper
• Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells

  2007cites this paper
• Therapeutic aspect of metastatic breast cancer: chemotherapy

  2007cites this paper
• Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer

  2007cites this paper
• Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.

  2006cites this paper
• Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients

  2006cites this paper
• Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.

  2006cites this paper
• Ocular presentations of breast cancer.

  2006cites this paper